Hair loss is one of chemotherapy’s most noticeable and despised side effects. Now U.S. researchers are about to put an experimental hair-preserving treatment to a rigorous test.
The Food and Drug Administration has expanded approval of Johnson & Johnson’s prostate cancer pill Zytiga for men with an earlier stage of the disease.
Does hope for cancer treatment lie in new drugs? Not necessarily, as new research shows that a commonly prescribed diabetes drug, metformin, may help fight cancer.
The federal government is stepping in to help ease the shortage of two life-saving cancer drugs, Doxil and methotrexate.
A drug that is commonly used to treat men with enlarged prostates may also delay the growth of prostate cancer, according to a new study.
President Barack Obama is directing the Food and Drug Administration to take steps to reduce drug shortages, an escalating problem that has endangered patients and raised the possibility of price gouging.
The Food and Drug Administration has approved a first-of-a-kind drug to treat the deadliest form of skin cancer by targeting a particular genetic mutation found in about half of patients.
The best-selling cancer drug in the world comes under federal scrutiny again this week, as drugmaker Roche makes a last-ditch effort to keep Avastin approved for breast cancer, despite the government’s opinion that it is ineffective against the disease.
As the Dallas Mavericks work to fend off the Miami Heat in the NBA Finals, a former Mavs player continues to fight a different kind of enemy – cancer. And, he’s done it all supported by his Mavericks teammates.
Nearly nine months ago, CBS 11 News began following a North Texas cancer patient as she started a new Dallas-based vaccine clinical trial. Find out how the vaccine is working and the changes it’s made in the Frisco mother’s life.
The Food and Drug Administration has granted Swiss drugmaker Roche a first-of-a-kind public hearing to defend the effectiveness of its drug Avastin for treating breast cancer.
One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from returning or extend life.